Abstract #0607: The age at diagnosis of SLE is rising in US based cohort📈 Those diagnosed ≥30 yrs were: ⬆️ More likely to have oral ulcers, hematologic features, +ANA ⬇️ Less likely to have malar rash or proteinuria @RheumNow #ACR25 https://t.co/pMPVLg1xTZ

Damen et al. 10-year follow-up of CRESPA study. Treatment withdrawl trial in early peripheral SpA. 38% in drug free remission. 82% in remission. @RheumNow #ACR25 Abstr#568 https://t.co/KOVW5pSbJg

DESIR cohort of early axSpA: ✳️Factors assoc w/ D2M axSpA - female sex, ⬆️ASDAS-CRP ⬆️BASFI ⬆️ASQOL at baseline. ✳️ Low prevalence of pts meeting D2M definition (15 pts - 8.4% bDMARD-treated) #ACR25 @RheumNow Abs0544 https://t.co/fBUh3myKcz

Abstract #0189: Rheumatologists are early adopters and high utilizers of #AI scribes. 📊 Adoption: 41% 🧑‍💻 Retention: 100% 💬 High utilizers (> 70% visits): 83%. The highest among IM subspecialties 🕒 AI scribes reduced EHR time across all measures. @RheumNow #ACR25 https://t.co/TBurWUKhMl

Ramiro et al. No significant differences seen between men and women in response to upadacitinib in AxSpA at week 14 or 52. Differs from data on TNFi/IL17i in this regard. Looks to me like men respond a bit quicker and better though... @RheumNow #ACR25 Abstr#589 https://t.co/2m7mrgcG0z

This retrospective cohort analysis by Dr. Lihi Eder et al showed that among patients with PsA, those w/ high dse activity & high 3VAS scores were assoc w/⬆️ risk of atrial tachyarrythmias. Main message: PsA conveys ⬆️CV risk; inflamm control is key! #ACR25 @RheumNow Abs0522 https://t.co/7sRM7K4V1c

In a nationally representative NHANES sample, inflammatory back pain (IBP) was not associated with HLA-B27 positivity or elevated CRP, regardless of IBP criteria used (e.g., Berlin 8a: OR 0.88, p=0.876). IBP alone may be insufficient for identifying axSpA-related immunogenetic or https://t.co/82NjVU171z

What can we learn from longitudinal peripheral blood multi-omic profiling in at-risk individuals? 50 RA converters vs. non converters from StopRA study Decision tree showing highest risk for conversion to clinical RA in Individuals w/ -CCP3 ≥108 units -T peripheral helpers https://t.co/jw53EB6tI6

#0774 Multi-omic profiling of anti-CCP3+ “at-risk” individuals reveals Tph & cytotoxic CD8+ expansions, altered gene/chromatin profiles and predictive model (AUC 0.77) for RA conversion PTPN22 locus accessibility & Tph ≥ 2.45% identify highest risk. @RheumNow #ACR25 https://t.co/JDSMkdmoGv

A new marker for stratification of ILD in dermatomyositis: Anti MDA5 antibodies! Japanese study MDA5 (201-300) positivity associated w/ Lower 6-month progression-free survival (43% vs. 74%) Lower 5-year survival rates (34% vs. 66%) Validation in other populations awaited https://t.co/IBiYyATer4